AbbVie updated its Q4 and full-year 2025 earnings guidance to reflect a significant expense related to acquired in-process research and development (IPR&D). The adjustment lowers the company's previously announced profit expectations for both periods.
Key Highlights
- The company announced a Q4 2025 acquired IPR&D and milestones expense of approximately $1.3 billion on a pre-tax basis, resulting in a negative impact of $0.71 to adjusted diluted EPS.
- Consequently, full-year 2025 adjusted diluted EPS guidance was reduced to a range of $9.90 - $9.94, down from the prior forecast of $10.61 - $10.65.
- The updated adjusted diluted EPS guidance for Q4 2025 is now projected to be $2.61 - $2.65, compared to the previous range of $3.32 - $3.36.